IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data

IN8BIO, INC.

2023-Q2 EPS reported -$0.57

Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.
Cash $17.0M as of June 30, 2023, up from $10.9M on March 31, 2023.
INB-200 Phase 1 data: 100% of treated GBM patients (n=8) exceeded median PFS; enrollment completion expected in 2023.
INB-400 Phase 2 trial in GBM on track to initiate enrollment in H2 2023; primary endpoint overall survival.
R&D day scheduled for October 12, 2023 in New York City; preclinical ovarian cancer data presented at ASGCT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IN8BIO, INC. reported the quarter ended June 30, 2023 results: net income $7.7 million, EPS $0.27 per basic and diluted common share.

Period: the quarter ended June 30, 2023
Net income: $7.7 million
EPS: $0.27 per basic and diluted common share
Result: reported results

Exact text from the filing

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-041481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.